Tumor growth suppression in C57BL/6J mice bearing LLC tumors treated with hPK5/NGR-hPK5 and cisplatin.
When the tumor size reached about 50 mm3, the mice were injected i.p. every other day with hPK5/NGR-hPK5 (on days 0, 2, 4, 6, 8 and 10; 6 times totally) and 24 h after each treatment mice were injected i.p. with cisplatin (on days 1, 3, 5, 7, 9 and 11; 6 times totally). The dose of hPK5 or NGR-hPK5 was 1.25 mg/kg/day in all protein therapy groups. Control mice were treated with injections of PBS. A, hPK5 combined with 2 mg/kg/day of cisplatin; B, NGR-hPK5 combined with 2 mg/kg/day of cisplatin; C, hPK5 combined with 0.5 mg/kg/day of cisplatin; D, NGR-hPK5 combined with 0.5 mg/kg/day of cisplatin. Tumor volume was calculated by the formula (L×W2×0.52). Eight to ten LLC tumor-bearing mice were used in each sample unit, and the data shown were the mean volume ± SE. * p<0.05.
